Published in J Virol on May 01, 1988
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med (1989) 2.89
Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol (1995) 2.87
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol (1992) 2.67
Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A (1993) 2.44
Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med (2005) 2.28
Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med (1994) 2.17
Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol (1989) 2.05
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol (1990) 1.99
Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol (1988) 1.97
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity. J Virol (1991) 1.93
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med (1995) 1.78
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol (1994) 1.66
Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol (1997) 1.63
Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. J Virol (1991) 1.62
Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol (2004) 1.55
Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol (1993) 1.51
Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol (2005) 1.34
Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J Virol (1996) 1.31
DNA immunization confers protection against murine cytomegalovirus infection. J Virol (1996) 1.22
Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol (2000) 1.16
Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood (2009) 1.14
Human T-cell responses to vaccinia virus envelope proteins. J Virol (2006) 1.14
Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J Virol (2000) 1.10
Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities. J Virol (2001) 1.06
Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals. Clin Exp Immunol (1990) 1.05
Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J Virol (1998) 1.05
Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol (2007) 0.98
CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol (2001) 0.95
Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev (1990) 0.92
Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins. J Virol (1990) 0.92
Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins. Clin Diagn Lab Immunol (1995) 0.90
Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J Virol (2003) 0.88
Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion. PLoS Pathog (2013) 0.86
Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection. Clin Exp Immunol (1991) 0.78
Editorial: Role of HLA and KIR in Viral Infections. Front Immunol (2016) 0.76
A Diverse Repertoire of CD4 T Cells Targets the Immediate-Early 1 Protein of Human Cytomegalovirus. Front Immunol (2015) 0.75
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Structural analysis of the major immediate early gene of human cytomegalovirus. J Virol (1984) 6.67
Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med (1982) 5.72
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell (1985) 5.25
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol (1985) 4.76
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol (1987) 4.58
Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell (1984) 3.97
Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology (1986) 3.59
Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature (1984) 3.26
Molecular cloning and physical mapping of murine cytomegalovirus DNA. J Virol (1983) 3.11
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J Virol (1987) 2.84
Vaccinia virus expression vectors. J Gen Virol (1986) 2.84
Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse. J Gen Virol (1977) 2.76
A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A (1985) 2.74
Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection. J Virol (1984) 2.62
The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol (1984) 2.44
Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus. J Virol (1985) 2.41
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30
Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol (1986) 2.13
The 89,000-Mr murine cytomegalovirus immediate-early protein activates gene transcription. J Virol (1986) 2.08
Biology of simian virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology (1980) 2.07
Virulence and attenuation of murine cytomegalovirus. Infect Immun (1971) 2.03
Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes. J Exp Med (1986) 1.88
A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J Exp Med (1987) 1.78
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J Immunol (1986) 1.65
Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol (1987) 1.62
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med (1987) 1.58
Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 1.57
A nonstructural polypeptide encoded by immediate-early transcription unit 1 of murine cytomegalovirus is recognized by cytolytic T lymphocytes. J Exp Med (1987) 1.52
Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. J Exp Med (1986) 1.50
Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes. J Virol (1987) 1.48
Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes. J Virol (1987) 1.47
The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol (1987) 1.41
Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. J Virol (1987) 1.38
Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus. J Virol (1986) 1.33
Immediate causes of death in acquired immunodeficiency syndrome. Arch Pathol Lab Med (1985) 1.20
Virulence characteristics of murine cytomegalovirus in cell and organ cultures. Infect Immun (1983) 1.09
Cytomegalovirus infection following marrow transplantation: risk, treatment, and prevention. Birth Defects Orig Artic Ser (1984) 1.06
Host immune response to reovirus: CTL recognize the major neutralization domain of the viral hemagglutinin. J Immunol (1982) 1.05
Altered serological and cellular reactivity to H-2 antigens after target cell infection with vaccinia virus. Nature (1975) 0.91
Cytomegalovirus: pathogenicity, immunity, and vaccine initiatives. J Infect Dis (1981) 0.86
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol (1985) 4.76
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol (1987) 4.58
Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23
Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol (2000) 4.09
Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol (2000) 3.35
Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature (1984) 3.26
Molecular cloning and physical mapping of murine cytomegalovirus DNA. J Virol (1983) 3.11
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med (1989) 2.89
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J Virol (1987) 2.84
A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature (1989) 2.76
Immune evasion by cytomegalovirus--survival strategies of a highly adapted opportunist. Trends Microbiol (1998) 2.75
Viral mechanisms of immune evasion. Immunol Today (2000) 2.74
A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A (1985) 2.74
A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism. Science (2001) 2.70
Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol (1992) 2.67
Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection. J Virol (1984) 2.62
Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis. Nat Biotechnol (1999) 2.61
Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med (1998) 2.60
A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity (1997) 2.49
A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45
The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol (1984) 2.44
Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus. J Virol (1985) 2.41
Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell (1989) 2.31
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30
A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J (1999) 2.30
Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med (1992) 2.29
The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med (1994) 2.26
Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med (1994) 2.17
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol (2002) 2.13
The 89,000-Mr murine cytomegalovirus immediate-early protein activates gene transcription. J Virol (1986) 2.08
Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. J Virol (1992) 2.08
Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol (1993) 2.04
Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol (1990) 2.00
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol (1990) 1.99
A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J (1997) 1.98
Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol (1988) 1.97
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med (1999) 1.88
Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus. J Virol (1986) 1.86
Viral mechanisms of immune evasion. Trends Microbiol (2000) 1.85
Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol (1997) 1.82
Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. J Virol (1995) 1.77
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
Forward with BACs: new tools for herpesvirus genomics. Trends Genet (2000) 1.66
Purification and properties of African swine fever virus. J Virol (1985) 1.65
Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell (1989) 1.64
Pseudorabies virus mutants lacking the essential glycoprotein gII can be complemented by glycoprotein gI of bovine herpesvirus 1. J Virol (1991) 1.64
Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J Virol (1999) 1.59
Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes. J Exp Med (1980) 1.58
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med (1987) 1.58
Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 1.57
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer. J Virol (1998) 1.56
A nonstructural polypeptide encoded by immediate-early transcription unit 1 of murine cytomegalovirus is recognized by cytolytic T lymphocytes. J Exp Med (1987) 1.52
The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med (2001) 1.52
Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol (1993) 1.51
Late-phase expression of a murine cytomegalovirus immediate-early antigen recognized by cytolytic T lymphocytes. J Virol (1986) 1.48
Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol (1998) 1.47
Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes. J Virol (1987) 1.47
Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol (1992) 1.46
Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J Immunol (1993) 1.45